LT2880180T - Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai - Google Patents

Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai

Info

Publication number
LT2880180T
LT2880180T LTEP13745117.5T LT13745117T LT2880180T LT 2880180 T LT2880180 T LT 2880180T LT 13745117 T LT13745117 T LT 13745117T LT 2880180 T LT2880180 T LT 2880180T
Authority
LT
Lithuania
Prior art keywords
kits
cancer
methods
screening patients
screening
Prior art date
Application number
LTEP13745117.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
Jérome Galon
Franck Pages
Bernhard Mlecnik
Gabriela BINDEA
Original Assignee
Institut National De La Santé Et De La Recherche Médicale (Inserm)
Université Paris Descartes
Assistance Publique Hôpitaux De Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut National De La Santé Et De La Recherche Médicale (Inserm), Université Paris Descartes, Assistance Publique Hôpitaux De Paris filed Critical Institut National De La Santé Et De La Recherche Médicale (Inserm)
Publication of LT2880180T publication Critical patent/LT2880180T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/158Expression markers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/16Primer sets for multiplex assays

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
LTEP13745117.5T 2012-08-06 2013-08-05 Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai LT2880180T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305975 2012-08-06
PCT/EP2013/066425 WO2014023706A1 (en) 2012-08-06 2013-08-05 Methods and kits for screening patients with a cancer

Publications (1)

Publication Number Publication Date
LT2880180T true LT2880180T (lt) 2019-01-25

Family

ID=46762994

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP13745117.5T LT2880180T (lt) 2012-08-06 2013-08-05 Būdai ir rinkiniai, skirti vėžiu sergančių pacientų atrankai

Country Status (13)

Country Link
US (2) US20150218650A1 (enExample)
EP (2) EP3470531A1 (enExample)
JP (2) JP6559566B2 (enExample)
AU (1) AU2013301609B2 (enExample)
CA (1) CA2881389C (enExample)
DK (1) DK2880180T3 (enExample)
ES (1) ES2702722T3 (enExample)
LT (1) LT2880180T (enExample)
PL (1) PL2880180T3 (enExample)
PT (1) PT2880180T (enExample)
SG (1) SG11201500922RA (enExample)
TR (1) TR201819211T4 (enExample)
WO (1) WO2014023706A1 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077634A1 (en) 2008-12-09 2010-07-08 Genentech, Inc. Anti-pd-l1 antibodies and their use to enhance t-cell function
EP3232199B1 (en) * 2014-08-19 2022-05-04 National University Corporation Okayama University Combination of immunosuppressive factor blocking agent and biguanide antidiabetic drug for use in a method of preventing progression of, treating and/or preventing cancer
WO2016109546A2 (en) * 2014-12-30 2016-07-07 Genentech, Inc. Methods and compositions for prognosis and treatment of cancers
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
CN110546277B (zh) 2017-03-01 2024-06-11 豪夫迈·罗氏有限公司 用于癌症的诊断和治疗方法
JP6565093B1 (ja) 2018-03-22 2019-08-28 住友電工ハードメタル株式会社 表面被覆切削工具およびその製造方法
US20210381058A1 (en) * 2018-10-01 2021-12-09 Nantomics, Llc Evidence based selection of patients for clinical trials using histopathology
WO2020245155A1 (en) 2019-06-03 2020-12-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for modulating a treatment regimen
IL291748A (en) 2019-11-07 2022-06-01 Oncxerna Therapeutics Inc Classification of growth microenvironments
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4172628A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
WO2022002873A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
CA3245129A1 (en) 2022-03-17 2023-09-21 Univ Paris Cite METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4888278A (en) 1985-10-22 1989-12-19 University Of Massachusetts Medical Center In-situ hybridization to detect nucleic acid sequences in morphologically intact cells
US5447841A (en) 1986-01-16 1995-09-05 The Regents Of The Univ. Of California Methods for chromosome-specific staining
US6280929B1 (en) 1986-01-16 2001-08-28 The Regents Of The University Of California Method of detecting genetic translocations identified with chromosomal abnormalities
US5427932A (en) 1991-04-09 1995-06-27 Reagents Of The University Of California Repeat sequence chromosome specific nucleic acid probes and methods of preparing and using
US5472842A (en) 1993-10-06 1995-12-05 The Regents Of The University Of California Detection of amplified or deleted chromosomal regions
US6942970B2 (en) 2000-09-14 2005-09-13 Zymed Laboratories, Inc. Identifying subjects suitable for topoisomerase II inhibitor treatment
JP2002363169A (ja) * 2001-06-08 2002-12-18 Fujiyakuhin Co Ltd 抗腫瘍活性を有する複素環化合物
US7711492B2 (en) * 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
US20110152115A1 (en) * 2003-09-03 2011-06-23 The United States of America, as represented by the Secretary, Department of Health and Methods for identifying, diagnosing, and predicting survival of lymphomas
US20060246524A1 (en) 2005-04-28 2006-11-02 Christina Bauer Nanoparticle conjugates
AU2006239315B2 (en) 2005-04-28 2012-03-01 Ventana Medical Systems, Inc. Enzymes conjugated to antiobodies via a PEG heterobifuctional linker
EP1777523A1 (en) 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
EP3095467B1 (en) 2005-11-23 2020-05-06 Ventana Medical Systems, Inc. Antibody-enzyme conjugate
US20110070582A1 (en) * 2008-11-03 2011-03-24 Source Precision Medicine, Inc. d/b/d Source MDX Gene Expression Profiling for Predicting the Response to Immunotherapy and/or the Survivability of Melanoma Subjects
EP2619576B1 (en) * 2010-09-24 2020-06-10 Niels Grabe Means and methods for the prediction of treatment response of a cancer patient
DK3141617T3 (en) * 2011-01-11 2019-02-25 Inst Nat Sante Rech Med PROCEDURE FOR PREVENTING THE CANCER OF A CANCER ON A PATIENT BY ANALYZING GENEPRESSION

Also Published As

Publication number Publication date
WO2014023706A1 (en) 2014-02-13
AU2013301609B2 (en) 2019-03-14
CA2881389A1 (en) 2014-02-13
SG11201500922RA (en) 2015-04-29
DK2880180T3 (en) 2019-01-14
JP6559566B2 (ja) 2019-08-14
ES2702722T3 (es) 2019-03-05
AU2013301609A1 (en) 2015-02-26
EP3470531A1 (en) 2019-04-17
JP6995091B2 (ja) 2022-01-14
PT2880180T (pt) 2018-12-27
US20150218650A1 (en) 2015-08-06
CA2881389C (en) 2022-01-04
PL2880180T3 (pl) 2019-04-30
JP2015530877A (ja) 2015-10-29
US20200299784A1 (en) 2020-09-24
TR201819211T4 (tr) 2019-01-21
EP2880180A1 (en) 2015-06-10
JP2019176880A (ja) 2019-10-17
EP2880180B1 (en) 2018-10-03

Similar Documents

Publication Publication Date Title
SG11201500922RA (en) Methods and kits for screening patients with a cancer
EP2776832A4 (en) BIOMARKER FOR BUBBLE CANCER AND METHOD FOR ITS USE
IL239262A0 (en) Scanning methods
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
IL235512A0 (en) New methods
EP2847593A4 (en) METHODS FOR PREDICTING AND DETECTING THE RISK OF CANCER
EP2841603A4 (en) METHODS OF ASSESSING THE STATUS OF LUNG CANCER
IL237436A0 (en) A method for screening cancer
EP2808681A4 (en) breathalyser
EP2908116A4 (en) SCREENING DEVICE AND SCREENING METHOD
EP2924691A4 (en) SCINTILLATE PANEL AND METHOD FOR PRODUCING A SCINTILLATE PANEL
GB201216289D0 (en) A screening procedure
IL236436A0 (en) Kits and methods for the detection of cyanide
SI2758532T1 (sl) Presejalni postopki in njihove uporabe
HUE046533T2 (hu) Eszközök és eljárások metán elõállítására
IL234080A0 (en) Tetrazolylhydroxyimino derivatives and methods for their production
SG11201501838RA (en) Completion assembly and methods for use thereof
GB201213770D0 (en) Screening methods
EP2721410A4 (en) BIOMARKERS FOR THE DIAGNOSIS AND TREATMENT OF EPITHELIAL CANCER
GB201221092D0 (en) Assemblies and methods
GB201202870D0 (en) Screening methods
GB201202945D0 (en) Novel cancer therapies and methods
GB201108085D0 (en) Novel cancer therapies and methods
GB201212964D0 (en) Diagnostic and prognostic methods
IL231330A0 (en) Cancer diagnosis methods